Novel imipridone combination therapies targeting oncohistone H3K27M mutant diffuse midline glioma (DMG)

被引：0
|
作者：
Borsuk, Robyn [1 ]
Zhou, Lanlan [2 ,3 ,4 ,5 ,6 ]
Lulla, Rishi [1 ]
El-Deiry, Wafik [2 ,3 ,4 ,5 ,6 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[2] Brown Univ, Joint Program Canc Biol, Providence, RI 02912 USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA
[5] Lifespan, Dept Med, Hematol Oncol Div, Providence, RI USA
[6] Brown Univ, Providence, RI 02912 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5407
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5407
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG).
    Borsuk, Robyn
    Zhou, Lanlan
    Zhang, Yiqun
    Prabhu, Varun V.
    Allen, Joshua E.
    Tapinos, Nikos
    Lulla, Rishi
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2021, 81 (13)
  • [2] H3K27M mutant diffuse midline glioma: a case report
    Luo, Y.
    Zeng, L.
    Xie, X-Q
    Wang, F.
    Liu, Y-Z
    Kang, J-B
    Li, X-F
    Wu, D-B
    Qu, B-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (05) : 2579 - 2584
  • [3] PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
    Borsuk, Robyn
    Zhou, Lanlan
    Zhang, Yiqun
    Prabhua, Varun
    Allen, Joshua
    Oster, Wolfgang
    Tapinos, Nikos
    Lulla, Rishi R.
    El-Deiry, Wafik
    NEURO-ONCOLOGY, 2020, 22 : 299 - 299
  • [4] Liquid biopsy in H3K27M diffuse midline glioma
    Patel, Jina
    Aittaleb, Rayan
    Doherty, Robert
    Gera, Ananya
    Lau, Benison
    Messinger, Dana
    Wadden, Jack
    Franson, Andrea
    Saratsis, Amanda
    Koschmann, Carl
    NEURO-ONCOLOGY, 2024, 26 : S101 - S109
  • [5] UNRAVELING H3K27M INTERACTIONS IN DIFFUSE MIDLINE GLIOMA
    Liapodimitri, Athanasia
    Lunsford, Kayleigh
    Tetens, Ashley R.
    Craig-Schwartz, Jordyn
    Vesuna, Farhad
    Raman, Venu
    Koldobskiy, Michael A.
    NEURO-ONCOLOGY, 2024, 26
  • [6] SHOULD LEPTOMENINGEAL DISSEMINATION (LMD) AT DIAGNOSIS WITH AN H3K27M MUTATION BE ENOUGH TO BE CONSIDERED A DIFFUSE MIDLINE GLIOMA (DMG) H3K27M ALTERED?
    La, Janet
    McGranahan, Tresa
    NEURO-ONCOLOGY, 2022, 24 : 154 - 154
  • [7] H3K27M mutation loss in a recurrent diffuse midline glioma
    Fecher, R.
    Iwamoto, F.
    McKhann, G.
    Goldman, J.
    Faust, P.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (06): : 440 - 440
  • [8] Treatment Dilemma of H3K27M Mutant Midline Glioma in Adults
    Uzel, Esengul Kocak
    Kilic, Melisa Bagci
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S792 - S793
  • [9] PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SHOWS ROBUST RESPONSE TO IMIPRIDONE BASED COMBINATION THERAPY
    Borsuk, Robyn
    Zhou, Lanlan
    Chang, Wen-i
    Zhang, Yiqun
    Prabhu, Varun
    Allen, Joshua
    Tapinos, Nikos
    Lulla, Rishi
    El-Deiry, Wafik
    NEURO-ONCOLOGY, 2021, 23 : 26 - 26
  • [10] Pediatric Non-Pontine Diffuse Midline Glioma H3K27M Mutant: A Monoinstitutional Experience
    Schiavello, E.
    Biassoni, V.
    Gattuso, G.
    Pecori, E.
    Diletto, B.
    Gandola, L.
    Massimino, M.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S193 - S194
12345